Showing 79 news articles about Injectable & long-acting PrEP

Filters Content type: News Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

Long-acting PrEP injection tolerable and acceptable for male volunteers, but dose adjustment needed

News
25 February 2016
Injectable & long-acting PrEP

Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex

News
1 November 2014
Injectable & long-acting PrEP

Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine

News
30 October 2014
Injectable & long-acting PrEP

Monkey studies confirm viability of injectable PrEP drug

News
5 March 2014
Vaginal rings & topical PrEP

Researchers and advocates discuss the microbicides pipeline in Europe

News
17 October 2013
Injectable & long-acting PrEP

Monthly injectable drug offers 100% protection against HIV in monkeys – could be dosed every three months

News
4 March 2013
Injectable & long-acting PrEP

Once-a-month HIV drug maintains good levels for prevention; few side-effects so far

News
7 March 2012